



UK Myeloma Society Spring Day

Controversies and Uncertainties – Unanswered Questions in Myeloma

Wednesday 20th March 2024

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

Joint Chairs: **Dr Sally Moore** (*University Hospitals Bristol and Weston*)
Dr Andrew Charlton (*Newcastle Upon Tyne Hospitals*)

09.00 *Registration*

09.25 Welcome and introduction

09.30 UK clinical practice changes

Dr Jonathan Sive, *UCLH*

09.45 UK trials practice changes

Dr Rakesh Popat, *UCLH*

What now for ASCT in myeloma?

10:00 4-drug Induction/ASCT/Len vs DRD for older transplant-eligible patients – which should we use?

Dr Kirsty Cuthill
King's College Hospital

Debate: Role of 1st ASCT – do we still need it at all?

10.20 Case and initial vote

10.25 For

Dr Ceri Bygrave
University Hospital of Wales

10.35 Against

Professor Guy Pratt
University Hospitals Birmingham

10.45 Q & A / Vote

10.55 *Coffee break*

11.25 Tandem auto in high risk newly diagnosed disease – should this be standard of care?

Dr Matthew Jenner
University Hospital Southampton

11.55 Panel discussion / Q&A on all ASCT talks

ASH Abstract Award winners

12.05 Investigating the functional impact of CRBN mutations on response to IMiD/ CELMoD agents in myeloma

Dr Yakinthi Chrysochoidou
Institute of Cancer Research, London
UKMS/GSK Bursary Winner

12.15 Targeted NGS panel guides risk-adapted treatment intention in newly diagnosed myeloma patients

Dr Gaurav Agarwal
Harvard University, Boston, USA
UKMS/Binding Site Bursary Winner

12.25 *Lunch and networking*

Continued over page

13.25	Michael Morley Lecture Bispecific Abs and CAR-T: sequencing, toxicities and practicalities	Prof Niels van de Donk Amsterdam University Medical Centre
	Debate: Early treatment vs 'monitoring' in biochemical relapse	
14.25	Case and initial vote	
14.30	Treat early	Dr Charlotte Pawlyn Institute of Cancer Research
14.40	Monitor	Dr Emma Searle Christie Hospital, Manchester
14.50	Q&A / Vote	
15.00	<i>Coffee break</i>	
	Debate: Should we treat high risk smouldering myeloma?	
15.30	Case and initial vote	
15.35	For	Dr Dean Smith University Hospitals Nottingham
15.45	Against	Dr Jaimal Kothari Oxford University Hospitals
15.55	Q & A / Vote	
16.05	<i>Summary and Close</i>	

Registration:

Standard Fee (until 3rd March):
£70 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 4th March):
£110 (£85 for Scientists, Nurses & Pharmacists)

Online registration is now open at www.collaborativeconferences.co.uk/ukmsociety

Please indicate if you wish to attend in person or watch the live stream while completing the registration form.

Enquiries: Please contact Alex (alex@collaborativeconferences.co.uk)

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

Premium Sponsors



Standard Sponsors



All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.